• News
  • SAN DIEGO
  • BioTech

JPMorgan recommends Acadia

The JPMorgan investment bank initiated coverage of Acadia Pharmaceuticals (Nasdaq: ACAD) on Thursday with a target price of $33, far above its current price in the $19 range.

The recommendation helped push Acadia's price 1.9 percent in morning trading on Wall Street, hitting $19.21 by noon Eastern time after closing at $18.87 on Wednesday, while the rest of the Nasdaq market dropped by 1.5 percent.

JPMorgan's move comes nine days after Acadia released its first-quarter financials, showing earnings of 19 cents per share compared to the Wall Street consensus projection of 13 cents. JPMorgan rated the company as "overweight" -- essentially a "buy" recommendation.

User Response
0 UserComments

Acadia Pharmaceuticals Inc.

Company Website

3911 Sorrento Valley Blvd.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ACAD
33.69
  -0.66  
- 1.92%
1,139,808,000
51.99
24.04

Insider Trade Data

Date Insider Shares Type Value
08/19/2015 Iversen, Leslie L 8,500 Exchange $93,500
08/11/2015 Kaplan, Lester J 8,500 Exchange $93,500
06/01/2015 Iversen, Leslie L 14,127 Exchange $125,024
06/01/2015 Iversen, Leslie L 14,127 Exchange $125,024
02/17/2015 Rasmussen, Torsten 19,847 Sell $695,544

Acadia Pharmaceuticals Inc. Executive(s):

Uli Hacksell

  • Chief Executive Officer, President

Similar Companies

NAICS - 541711 - Research and Development in Biotechnology